Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy
Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Jonathan C. Fox(Amyloidosis Foundation), Keyur B. Shah(Amyloidosis Foundation), Mazen Hanna(Amyloidosis Foundation), James E. Hoffman(Amyloidosis Foundation), Steen Hvitfeldt Poulsen(Amyloidosis Foundation), Simon Gibbs(Amyloidosis Foundation), Marianna Fontana(Johnson & Johnson (United States)), Mathew S. Maurer(Boston University), Pablo García‐Pavía(Universidad Francisco de Vitoria), Haolin Xu(Amyloidosis Foundation), Laura Obici(Amyloidosis Foundation), Martha Grogan(Boston University), Daniel P. Judge(Johns Hopkins University), Jyotsna Garg(Clinical Research Institute), Francesco Cappelli(Fondazione Toscana Gabriele Monasterio), Uma Sinha(Amyloidosis Foundation), Prem Soman(Amyloidosis Foundation), Frank W. Rockhold(Amyloidosis Foundation), José Nativi-Nicolau(Amyloidosis Foundation), Xiaofan Cao(Amyloidosis Foundation), Ahmad Masri(Oregon Health & Science University), Karen Chiswell(Amyloidosis Foundation)
Cited by 453
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k